Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DA-EPOCH-R Appears More Toxic Than Standard R-CHOP in DLBCL

Publish date:: June 28, 2019

Key clinical point: Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) was found to be more toxic than R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: After a median follow-up of 5.2 years, no significant difference in progression-free survival was seen between the study arms (DA-EPOCH-R hazard ratio, 0.93; 95% confidence interval, 0.68-1.27; P = .65).

Study details: A phase 3 trial of 491 patients with DLBCL.

Disclosures: The study was supported by the National Cancer Institute. The authors reported financial relationships with Bristol-Myers Squibb, Celgene, Janssen, Jazz Pharmaceuticals, Morphosys, and others companies.

Citation:

Bartlett NL et al. J Clin Oncol. 2019 Apr 2. doi: 10.1200/JCO.18.01994.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,